A new and important potential role for ACE inhibitors is suggested by the recent trials in patients with low ejection fraction, which documented a significant reduction in major ischemic events such as myocardial infarction, unstable angina, and the need for coronary revascularization procedures. In addition, parallel epidemiological, genetic, and experimental studies suggest that the renin-angiotensin-aldosterone system may have a role in the development of coronary artery disease
ngiotensin-converting enzyme (ACE) inhibitors are commonly used drugs in the management of a variety of cardiovascular diseases. They are effective antihypertensive agents. [1] [2] [3] Early studies have demonstrated reductions in mortality and symptoms of heart failure in patients with severe congestive heart failure.4 More recently, clinical trials have demonstrated reductions in mortality and in hospitalizations for heart failure when these agents were used in patients with moderate left ventricular dysfunction, with and without overt heart failure, further expanding the clinical value of these drugs in the management of patients with cardiac diseases. These benefits have been observed consistently in several trials,5-7 in patients with ischemic and nonischemic causes for the left ventricular dysfunction and with or without recent myocardial infarction. The reductions in progressive heart failure and mortality in these patients are at least partly related to a beneficial effect on left ventricular remodeling and reductions in left ventricular enlargement. [8] [9] [10] Other potential beneficial effects of these agents, such as regression of left ventricular hypertrophy and retardation of the rate of loss of renal function in patients with diabetic nephropathy, have been brought into focus by recent trials and also by experimental studies that explore their mechanisms of action.
A new and important potential role for ACE inhibitors is suggested by the recent trials in patients with low ejection fraction, which documented a significant reduction in major ischemic events such as myocardial infarction, unstable angina, and the need for coronary revascularization procedures. In addition, parallel epidemiological, genetic, and experimental studies suggest that the renin-angiotensin-aldosterone system may have 
Antiproliferative and Antimigratory Effects
Data from both in vitro and in vivo studies91-97 show that angiotensin II can produce vascular smooth muscle cell growth and proliferation, a mechanism important in the genesis and progression of atherosclerotic lesions. In animal models, angiotensin II acts by the induction of proto-oncogenes c-fos,98-100 c-myc,97,101 and c-]un102 '103 and induces the expression of several growth factor genes, such as the genes encoding for the a-chain of platelet-derived growth factor, transforming growth factor-f3, and thrombospondin.97104-106 Early activation of these proto-oncogenes followed by sequential activation of growth factor genes (and possibly other genes involved in cell growth) ultimately result in vascular smooth muscle cell growth. In addition to the trophic effect on vascular smooth muscle cells, angiotensin II has been shown to release an endothelial neutrophil chemoattractant ( 
Long-term Trials in Patients With Heart Failure and Low Ejection Fraction
Three recent large randomized trials in patients with low left ventricular ejection fraction followed over a period of >3 years reported significant reductions in myocardial infarction with the use of ACE inhibitors: The SOLVD trials included patients with left ventricular ejection fraction of <0. 35 . Patients with congestive heart failure entered the Treatment Trial,5 and those without overt heart failure and receiving no therapy for heart failure entered the Prevention Trial.6 Patients in both trials had not sustained a recent myocardial infarction in the month before enrollment, nor did they have unstable angina or any clear indications for revascularization at study entry. The SAVE trial7 enrolled patients within 3 to 16 days after inyocardial infarction Table 2 . The main end points in the SOLVD and SAVE trials was mortality. Development of myocardial infarction was a predefined secondary end point in these studies, and data on myocardial infarction were therefore prospectively and systematically collected. A significant risk reduction (RR) in the incidence of myocardial infarction was observed in each of these three long-term trials, and all were of similar with and without a history of diabetes, and against a background of different drugs (,-blockers, aspirin, calcium channel blockers). Furthermore, reductions in ischemic events were observed both among patients with overt congestive heart failure, who probably had elevations in plasma renin levels, and in patients without heart failure, who presumably did not have elevated plasma renin levels in the absence of diuretic therapy. 151 In addition, the observed reduction in ischemic events cannot be explained by the hypotensive actions of ACE inhibitors alone, since the magnitude of risk reduction was substantially larger than that expected from shortterm, modest reductions in blood pressure. In a recent meta-analysis of 14 randomized clinical trials of antihypertensive therapy, diastolic blood pressure reductions of 5 to 6 mm Hg for about 4 to 5 years resulted in a 14% reduction in fatal and nonfatal coronary heart disease events.132 In the combined SOLVD trials, diastolic blood pressure was reduced by an average of 4 mm Hg, and this was associated with a 23% reduction in fatal or nonfatal myocardial infarctions and a 21% reduction in cardiac deaths. Moreover, the risk reductions in ischemic events were similar in patients with different levels of systolic and diastolic blood pressure at baseline. There was a trend toward larger reductions in myocardial infarction and unstable angina among those with a greater reduction in blood pressures; however, these differences did not reach statistical significance. These considerations suggest that the reduction in major ischemic events observed with ACE inhibitor therapy is at least in part due to mechanisms unrelated to the hypotensive effects of these agents.
Analysis of the time course of this observed reduction in ischemic end points may also provide insights into potential mechanisms of action of ACE inhibitors. Both arms of the SOLVD trials, as well as the SAVE trial, found little difference in the incidence of myocardial infarction during the first 6 months after randomization (Figure) . Differences were apparent after 6 months of treatment and continued to widen thereafter. A very similar time course of events was noted in the SOLVD trials for hospitalizations for unstable angina. This delay in the reduction of ischemic events resembles the "lag" observed in trials of cholesterol lowering and suggests that the mechanism for this observed anti-ischemic action of ACE inhibitors is unlikely to be related solely to the beneficial hemodynamic effect of the drug, which is observed immediately and which is not expected to increase with time. These observations suggest that ACE inhibitors decrease the incidence of ischemic events, which may be related to multiple mechanisms, including the prevention of the progression of coronary atherosclerosis and/or stabilization of atherosclerotic plaques. Although hemodynamic changes alone are unlikely to explain the anti-ischemic action of ACE inhibitors, it is possible that the continued reduction in myocardial oxygen consumption related to the effects of these drugs on afterload, preload, left ventricular geometry, and ventricular mass, possibly in conjunction with direct vascular protective effects, leads to reductions in myocardial infarction and unstable angina.
The recent AIRE study147 randomized 2006 patients within 3 to 10 days after acute myocardial infarction who exhibited transient or persistent symptoms or signs of heart failure to treatment with the ACE inhibitor ramipril or to placebo. Patients were followed for an average of 15 months (minimum duration of follow-up was 6 months). A highly significant and substantial reduction in all-cause mortality, the primary study end point, was demonstrated (RR, 27%; 95% CI, 11% to 40%; P=.002), and this benefit was apparent earlier and reached statistical significance after a much shorter duration of follow-up than in the SAVE trial. Reinfarction rates were recorded prospectively. While a trend toward fewer acute myocardial infarcts was noted in patients treated with ramipril, this was not statistically significant: there were 81 recurrent infarcts (8%) in ramipril-treated patients versus 88 (9%) in patients allocated to placebo. These results do not necessarily contradict the results of the SOLVD and SAVE trials. The number of validated recurrent myocardial infarcts in the AIRE study was relatively small, largely due to the much shorter average follow-up period. The favorable trends observed are consistent with the observations made after a similar duration of follow-up in the SOLVD and SAVE trials. Even though the duration of treatment and follow-up in the AIRE study is relatively short, if these results are combined with the SOLVD and SAVE trials, the reduction in myocardial infarction risk still remains highly significant (Table 3) .
Other The CONSENSUS II triall53 randomized 6090 patients with acute myocardial infarction presenting within 24 hours of onset of symptoms to treatment with enalapril intravenously followed by oral therapy administered for 6 months versus placebo. No benefit was noted with regard to mortality (6-month mortality was 10.2% in the placebo and 11.0% in the enalapril group) or reinfarction (6-month reinfarction rates were 9% [total number 268] in the placebo and 9% [total number 271] in the enalapril group). These results do not necessarily contradict the observations from the SOLVD and SAVE trials, which did not observe differences in ischemic events until after about 6 months of treatment.
The value of ACE inhibitors initiated early in the setting of acute myocardial infarction ( Table 4 shows the results of these large trials, summarizing data from more than 90 000 patients randomized to ACE inhibitor therapy or placebo in the early phases of acute myocardial infarction. A small but statistically and clinically significant benefit is observed. The benefits, however, appear to be larger (about 10 lives prolonged for every 1000 patients treated) in high-risk patients (eg, those with anterior infarction, previous infarction, or heart failure at entry).
These trials provide convincing evidence for the benefit of treatment with ACE inhibitors early in the course of acute myocardial infarction, which is likely to be due to hemodynamic effects. However, they do not address whether further major ischemic events will be prevented by these drugs because of their short duration of treatment. There was no effect on angiographic restenosis and clinical events at 6 months. Similar results were reported with higher doses of cilazapril in the MARCA-TOR90 study. These results contrast with the efficacy of cilazapril in the prevention of restenosis after balloon injury in the rat carotid artery model82 and the atherosclerotic rabbit iliac artery model.83 In the animal model, treatment was initiated before PTCA, whereas in the above clinical trials, treatment was initiated after PTCA. It is likely that the very potent and complex wound-healing process after angioplasty may differ in its responsiveness to ACE inhibitors compared with coronary artery disease not affected by invasive interventions. Furthermore, although the relatively short duration of therapy and follow-up of 6 months may have been adequate to evaluate the effects on restenosis, it may have been too short to detect differences in progression of native vessel atherosclerosis. This possibility is supported by the long-term follow-up in the MER-CATOR trial, which indicated a trend toward fewer clinical cardiac end points, such as death, myocardial infarction, and coronary revascularization after 12 months of follow-up in cilazapril-treated patients. 157 Trials in Stable Angina Pectoris Several small trials assessing the effects of ACE inhibitors on severity of angina pectoris and/or on myocardial ischemia have reported conflicting results,158-166 with benefit in some patients and no benefit or even exacerbation of angina in others, indicating that ACE inhibitors do not have consistent antianginal effects in short-term studies. Although reductions in the incidence of myocardial infarction and cardiac death are not expected to become apparent in these small studies on the basis of sample size alone (limited power), it is also of note that these were again investigations characterized by a short duration of therapy (6 weeks to <6 months) and therefore cannot answer questions related to the long-term efficacy of ACE inhibitor therapy in preventing major acute ischemic events by mechanisms other than acute hemodynamic changes. Sogaard et al'66 evaluated the effects of captopril on spontaneous, ambulatory ST-segment depression and on exercise-induced ST-segment depression in patients with recent myocardial infarction and left ventricular dysfunction. Both ambulatory and exerciseinduced ischemia were significantly decreased by treatment with captopril. Statistically significant differences in ambulatory ST-segment depression between captopril-and placebo-treated patients became apparent after 3 months of therapy and continued to widen thereafter, being more pronounced at 6 months, while differences in exercise-induced ischemia occurred only after 6 months of therapy. These results can be explained by a continued improvement in the balance between myocardial oxygen demand and supply related to myocardial remodeling resulting in decreased left ventricular volume, concomitant reduction in both preload and afterload, and increased coronary perfusion and peripheral arterial compliance. The time course of the observed changes also suggests the possibility of other anti-ischemic effects, such as direct effects of ACE inhibition on vascular remodeling, antithrombotic effects, and effects on platelet and fibrinolytic activity. Current Ongoing Trials Several studies are currently under way examining the "anti-ischemic" and "antiproliferative" effects of ACE inhibitors. These studies vary in design (ie, examination of lesion development or progression by angiographic or ultrasound measures or impact on clinical end points) and consequently sample size and duration of follow-up. Key aspects of these trials are summarized in Table 5 . Conclusions
In summary, there is promising information indicating a potential role for ACE inhibitors in reducing 
